Clinical Trials on Keratoderma, Palmoplantar in Belgium

Total 4 results

Boehringer Ingelheim

Completed

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

Palmoplantar Pustulosis (PPP)

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Hungary, Netherlands, Czechia, Poland
Boehringer Ingelheim

Terminated

A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab

Palmoplantar Pustulosis

United Kingdom, Korea, Republic of, United States, Canada, Belgium, Australia, Taiwan, Japan, France, Germany, Russian Federation, Czechia, Hungary, Poland
Novartis Pharmaceuticals

Completed

Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

Palmoplantar Pustular Psoriasis

Germany, Belgium, Austria, Italy, Spain, France, Sweden, United Kingdom, Russian Federation, Poland
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland

3

Subscribe